Cross-referencing clinical data
A pairing appears on this page only when a trial gave both ingredients together and measured the result. Eclipta has none that clears that bar.
Stitching two separate single-ingredient studies into a pairing is the one thing this engine will not do. When a study of the combination itself holds up at source, it lands here with its citation.
No invented synergy. Where actives were studied on their own rather than together, the record shows each on its own evidence, never a combined effect no trial measured.
Research strength. Research strength says how much work stands behind the combination. It is never a product score.
Independent record. Every finding is cited to a named trial, dated, and never written by the brand.
20 pairings are live across the library today. Checked 20 July 2026.
No study gave these as a pair, so they are not in the card above. But the reason they belong together is settled biochemistry, not a guess, so it is worth knowing.
Eclipta alba carries wedelolactone and related coumestans, and silymarin carries flavonolignans; both classes have been examined in liver models. Products combine them on that shared rationale. No human trial has tested the pair. The grounding is chemical class overlap plus long parallel use, not measured combination effect.
Bhringraj and ashwagandha sit together in a large number of traditional Ayurvedic formulations and in modern hair and vitality blends. The pairing reflects a shared classification within that system rather than a demonstrated pharmacological interaction. Nothing has been measured for the combination in people. The pairing is formulation convention.
Phenolic and coumestan constituents carry the hydroxyl groups that bind ferric iron and form poorly absorbed complexes. This is established chemistry for polyphenol-rich plant material generally and applies here by class. Anyone taking an iron supplement should space it a couple of hours from a concentrated Eclipta extract. The effect is on absorption, which is a measured step and not the same as an effect on iron status.
Wedelolactone and the flavonoids in Eclipta are subject to fast glucuronidation, the same clearance route piperine inhibits. Adding piperine to a botanical blend is standard practice for that reason. The direction is predictable from the mechanism; the magnitude for these specific constituents has not been measured. More exposure also means more of whatever unwanted effects the extract carries.
Eclipta is the flagship traditional hair botanical in Ayurveda and biotin is the flagship modern hair nutrient, so they end up in the same bottle constantly. Biotin's role as a carboxylase cofactor is settled biochemistry but only matters where status is genuinely low. The two act through unrelated routes, so the pairing is complementary rather than synergistic. It is formulation convention with a reasonable logic.
The classical preparation is an oil infusion, which pulls the lipophilic constituents out of the plant into the fat phase. That is a genuine extraction step, not just a carrier choice. It also determines what ends up in a topical product, since water-soluble constituents largely stay behind. The route is traditional and well documented; effects on hair have not been established in controlled human work.
Both are staples of Ayurvedic preparation and both suffer from poorly absorbed key constituents that get conjugated quickly. Formulators handle them the same way, with lipid vehicles and piperine. That shared handling is the main practical link between them. No combination data exists in people.
The coumestan and flavonoid constituents in Eclipta become phenoxyl radicals after quenching a radical, and ascorbate can reduce them back. This recycling is standard antioxidant network chemistry and is not specific to this plant. It supports co-formulation on chemical grounds. It does not by itself support any outcome claim.
Nothing specific on file for Eclipta. Match the label to the daily amount above, and tell your doctor what you take.
Not medical advice. Show the label to your pharmacist.These are the studies our verdict leans on, chosen from the 2 we read for Eclipta. The full linked list is below.
2 sources behind our Eclipta verdict: peer-reviewed studies and registered clinical trials. Every one links straight to PubMed, the journal, or ClinicalTrials.gov. Read them yourself.
Evidence surfaced via Semantic Scholar (Allen Institute for AI) and ClinicalTrials.gov. Ranked by study type and citation weight, not cherry-picked.
Read this carefully. These are 37 voluntary, unverified reactions reported to the FDA (openFDA). The number mostly reflects how popular Eclipta is, not how risky it is. A report is not proof Eclipta caused anything. It is a signal of what to watch for, nothing more.
Source: openFDA adverse-event reports. Voluntary reporting, not an incidence rate.
FDA Disclaimer: These statements have not been evaluated by the Food and Drug Administration. This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. Consult your healthcare provider before starting any supplement regimen.